N-(3-溴苯基)-5-氯戊酰胺 | 848170-46-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3-溴苯基)-5-氯戊酰胺
• 英文名称: N-(3-bromophenyl) 5-chloropentanamide
• 英文别名: N-(3-Bromophenyl)-5-chloropentanamide
• CAS: 848170-46-7
• 化学式: C₁₁H₁₃BrClNO
• 分子量: 290.587
• InChiKey: NDBSJMMDTUMTJE-UHFFFAOYSA-N

物化性质

• 沸点：
  430.4±30.0 °C(Predicted)
• 密度：
  1.455±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(3-溴苯基)-5-氯戊酰胺 在 甲醇 、 水 作用下， 以 乙腈 为溶剂， 反应 9.67h， 生成 [N-(3-bromophenyl)carbamoyl]butylphosphonic acid
  参考文献：
  名称：

  Exploring DOXP-reductoisomerase binding limits using phosphonated N-aryl and N-heteroarylcarboxamides as DXR inhibitors

  摘要：

  DOXP-reductoisomerase (DXR) is a validated target for the development of antimalarial drugs to address the increase in resistant strains of Plasmodium falciparum. Series of aryl- and heteroarylcarbamoylphosphonic acids, their diethyl esters and disodium salts have been prepared as analogues of the potent DXR inhibitor fosmidomycin. The effects of the carboxamide N-substituents and the length of the methylene linker have been explored using in silico docking studies, saturation transfer difference NMR spectroscopy and enzyme inhibition assays using both EcDXR and PfDXR. These studies indicate an optimal linker length of two methylene units and have confirmed the importance of an additional binding pocket in the PfDXR active site. Insights into the constraints of the PfDXR binding site provide additional scope for the rational design of DXR inhibitors with increased ligand-receptor interactions. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.04.076
• 作为产物：
  描述：

  5-氯代戊酰氯 、 间溴苯胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 N-(3-溴苯基)-5-氯戊酰胺
  参考文献：
  名称：

  一系列新的喹啉衍生物的合成，构效关系和受体药理作用，它们是选择性的，非竞争性的mGlu1拮抗剂。

  摘要：

  我们描述了发现和一系列新的喹啉衍生物作为选择性和高效非竞争性mGlu1拮抗剂的结构和活性之间的关系。我们首先基于CHO-K1细胞中表达的大鼠mGlu1受体的细胞信号转导试验，将cis-10鉴定为一种相当有效的mGlu1拮抗剂（IC（50）= 20 nM），然后我们能够进行设计和合成以化合物cis-64a为例，对大鼠和人mGlu1受体均具有高度有效的化合物，该化合物对人mGlu1受体的拮抗效力为0.5 nM。我们简要介绍并讨论了人肝微粒体中化合物的体外代谢稳定性。我们最终报告了我们的先导化合物cis-64a的药代动力学特性。

  DOI：

  10.1021/jm049499o

文献信息

• Synthesis, Structure−Activity Relationship, and Receptor Pharmacology of a New Series of Quinoline Derivatives Acting as Selective, Noncompetitive mGlu1 Antagonists
  作者：Dominique Mabire、Sophie Coupa、Christophe Adelinet、Alain Poncelet、Yvan Simonnet、Marc Venet、Ria Wouters、Anne S. J. Lesage、Ludy Van Beijsterveldt、François Bischoff

  DOI：10.1021/jm049499o

  日期：2005.3.1

  We describe the discovery and the structure-activity relationship of a new series of quinoline derivatives acting as selective and highly potent noncompetitive mGlu1 antagonists. We first identified cis-10 as a fairly potent mGlu1 antagonist (IC(50) = 20 nM) in a cell-based signal transduction assay on the rat mGlu1 receptor expressed in CHO-K1 cells, and then we were able to design and synthesize

  我们描述了发现和一系列新的喹啉衍生物作为选择性和高效非竞争性mGlu1拮抗剂的结构和活性之间的关系。我们首先基于CHO-K1细胞中表达的大鼠mGlu1受体的细胞信号转导试验，将cis-10鉴定为一种相当有效的mGlu1拮抗剂（IC（50）= 20 nM），然后我们能够进行设计和合成以化合物cis-64a为例，对大鼠和人mGlu1受体均具有高度有效的化合物，该化合物对人mGlu1受体的拮抗效力为0.5 nM。我们简要介绍并讨论了人肝微粒体中化合物的体外代谢稳定性。我们最终报告了我们的先导化合物cis-64a的药代动力学特性。
• [EN] HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PRMT5
  申请人：ANGEX PHARMACEUTICAL INC

  公开号：WO2020243178A1

  公开（公告）日：2020-12-03

  The present disclosure describes novel heterocyclic PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorders are also described.

  本公开描述了新颖的杂环PRMT5抑制剂以及制备它们的方法。还描述了包含这些PRMT5抑制剂的药物组合物以及用于治疗癌症、传染病和其他PRMT5相关疾病的方法。
• Exploring DOXP-reductoisomerase binding limits using phosphonated N-aryl and N-heteroarylcarboxamides as DXR inhibitors
  作者：Taryn Bodill、Anne C. Conibear、Marius K.M. Mutorwa、Jessica L. Goble、Gregory L. Blatch、Kevin A. Lobb、Rosalyn Klein、Perry T. Kaye

  DOI：10.1016/j.bmc.2013.04.076

  日期：2013.7

  DOXP-reductoisomerase (DXR) is a validated target for the development of antimalarial drugs to address the increase in resistant strains of Plasmodium falciparum. Series of aryl- and heteroarylcarbamoylphosphonic acids, their diethyl esters and disodium salts have been prepared as analogues of the potent DXR inhibitor fosmidomycin. The effects of the carboxamide N-substituents and the length of the methylene linker have been explored using in silico docking studies, saturation transfer difference NMR spectroscopy and enzyme inhibition assays using both EcDXR and PfDXR. These studies indicate an optimal linker length of two methylene units and have confirmed the importance of an additional binding pocket in the PfDXR active site. Insights into the constraints of the PfDXR binding site provide additional scope for the rational design of DXR inhibitors with increased ligand-receptor interactions. (C) 2013 Elsevier Ltd. All rights reserved.